Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8010 in Advanced or Metastatic Solid Tumors
NCT05848466Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8010 in solid tumor (8 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 3 weeks and Maximum tolerated dose at 3 weeks. Started Feb 2023; status: completed.
02
Drugs
BAT8010
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05848466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848466.